以下內(nèi)容僅供參考,實(shí)際診斷及用藥請遵從醫(yī)生指導(dǎo),使用前請仔細(xì)閱讀楷萊/鹽酸多柔比星脂質(zhì)體注射液說明書;祝廣大病患者早日康復(fù)!
 
【藥品名稱】
通用名稱：鹽酸多柔比星脂質(zhì)體注射液
商品名稱：楷萊注射液
英文名稱：Caelyx 

【yw分類】
抗腫瘤kss類

【成    分】
鹽酸多柔比星脂質(zhì)體 liposomal doxorubicin HCl 

【化學(xué)名稱】
(1S,3S)-3-乙醇酰-1,2,3,4,6,11-六氧-3,5,12-三羥基-10-甲氧基-6,13-二氧并四苯-1-基-3-氨基-2,3,6-三去氧-α-L-來蘇吡喃糖苷。分子式：C27H29NO11 · HCl，分子量 ：579.99。 　

【性狀】
本品這種工藝被稱作為空間穩(wěn)定或隱匿，可以保護(hù)脂質(zhì)體免受單核巨噬細(xì)胞系統(tǒng)（MPS）識(shí)別，從而延長其在血液循環(huán)中的時(shí)間。楷萊本品為無菌、半透明的紅色混懸液，每瓶10 mL，含鹽酸多柔比星2 mg/mL，是用于單劑量靜脈滴注給藥的濃縮液。本品的活性成分為鹽酸多柔比星，是從一種波塞鏈霉菌表灰變種（strep tomyces peucetius var. caesius）培養(yǎng)液中提取得到的蒽環(huán)類細(xì)胞毒性kss。

【適 應(yīng) 癥】
本品可用于低CD4（<200 CD4淋巴細(xì)胞/mm3）及有廣泛皮膚粘膜內(nèi)臟疾病的與艾滋病相關(guān)的卡波氏肉瘤（AIDS-KS）病人。

【用法用量】
本品應(yīng)為每2-3周靜脈內(nèi)給藥20 mg/m2，給藥間隔不宜少于10天，因?yàn)椴荒芘懦齳w蓄積和毒性增強(qiáng)的可能。病人應(yīng)持續(xù)zl2-3個(gè)月以產(chǎn)生療效。為保持一定的療效，在需要時(shí)繼續(xù)給藥。本品用250毫升5%葡萄糖注射液稀釋，靜脈滴注30分鐘以上。禁止大劑量注射或給用未經(jīng)稀釋的藥液。建議本品滴注管與5%葡萄糖滴注管相連接以進(jìn)一步稀釋并{zd0}限度地減少血栓形成和外滲危險(xiǎn)。

【規(guī)格】
注射液 20mg x 10 mL/支  4150元/盒

【貯藏】
未開封的藥瓶應(yīng)保存在2-8°C環(huán)境下，避免冷凍。本品用5%葡萄糖注射液稀釋后供靜脈滴注的藥液應(yīng)立即使用。稀釋液不立即使用時(shí)應(yīng)保存在2-8°C環(huán)境下，不超過24小時(shí)。

【生產(chǎn)企業(yè)】
先靈葆雅

【有效期】
18個(gè)月

【英文版】
Zydus Cadila has introduced an NDDS product 'Nudoxa' for the treatment of various cancers. One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach in cancer therapy.

With chemotherapy being a common mode of treatment in cancers, there has been a long standing need for a drug that is stable and long lasting with reduced toxicity and side effects. Nudoxa addresses this need. A patented product in India and South Africa, patents for Nudoxa have also been filed in EU, US, Japan and several countries globally.

Doxorubicin, the first generation drug, was launched in 1960s and gave a new lease of life to cancer patients with its ability to combat aggressive and malignant tumours. This DNA-interacting drug, however, was discovered to cause life-threatening side effects in the form of cardiac abnormalities.

An advancement on this therapy resulted in liposomal doxorubicin in which the molecules of the drug are encapsulated in a fatty coating known as liposomes. The liposomes allow the doxorubicin to be delivered specifically in greater amounts to the cancer cells, while having fewer side effects on the healthy tissues. A further advancement in this line of treatment was the Pegylated-liposomal doxorubicin, a unique form of liposomal doxorubicin in which the liposomes are coated with polyethylene glycol, leading to a much longer half-life in the blood. However Pegylated-liposomal doxorubicin are likely to cause ‘Hand-Foot Syndrome,' characterized by skin eruptions on the palms of the hand or soles of the feet, leading to interruption in therapy.

A new variant of liposomal doxorubicin, Nudoxa with its unique drug delivery system is a breakthrough in cancer therapy as it offers the benefits of Pegylated-liposomal doxorubicin without its major side effects like the Hand Foot syndrome. Marketed by Zydus Biogen, Nudoxa is manufactured by Zydus-BSV Pharma Pvt. Ltd., the joint venture company of Zydus Cadila and Bharat Serums and Vaccines Pvt. Ltd. Founded in 2005, Zydus-BSV Pharma focuses on targeted therapies in the area of Oncology.

Nudoxa is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer - the second most common type of cancer, ovarian cancer - the fifthleading cause of cancer death in women, and AIDS-related Kaposi sarcoma which develops in people who are infected with the human immunodeficiency virus (HIV).

——★ 1 我們盡心盡力為您代查、供應(yīng)、代購藥品，品類齊全。
——★ 2 我們僅提供藥品信息服務(wù),不提供在線交易。
——★ 3 藥品資料及價(jià)格信息僅作參考，我們將按照國家對藥品的流通監(jiān)督管理的相關(guān)規(guī)定為您提供相應(yīng)需求服務(wù)。
——★ 4詳情請咨詢SR鄭州雙瑞醫(yī)藥公司客服人員：舒小姐 13949001479